ONYEMA AMAKIRI: Open Payments
NPI 1811166721 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$961 in 43 payments from 15 companies in 2025. Trend: 2023 $1,444 · 2024 $1,572 · 2025 $961
Food & beverage: $880Education: $81
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $224 |
| Teva Pharmaceuticals USA, Inc. | 6 | $164 |
| Viatris Specialty LLC | 4 | $111 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $73 |
| Lilly USA, LLC | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $52 |
| Novo Nordisk Inc | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
Products named: FARXIGA, YUPELRI, AUSTEDO XR, REXULTI, Kerendia, JARDIANCE, AIRSUPRA, MOUNJARO.
Industry payments across TX — which companies pay providers there.
